Pantethine

Pantethine

1. Identity: Chemical Names, Natural Sources, and Common Forms

1.1 Chemical Identity

Pantethine (also called bis-pantethine or co-enzyme pantethine) is a dimeric form of pantetheine, which is produced from pantothenic acid (vitamin B5) by the addition of cysteamine. It is made of two molecules of pantetheine joined by a disulfide bond — a chemical bond between two molecules of sulfur. It is also known by the systematic chemical names D-bis(N-pantothenyl-beta-aminoethyl)disulfide and (R)-N,N′-[dithiobis(ethyleneimino-carbonylethylene]bis(2,4-dihydroxy-3,3-dimethylbutyramide). Its molecular formula is C₂₂H₄₂N₄O₈S₂ and its molecular weight is 554.73 daltons. Its CAS registry number and PubChem Compound ID (CID 452306) are recorded in the NIH PubChem database.

Pantethine is the stable disulfide form of pantetheine, and is the major precursor of coenzyme A (CoA), which plays a central role in the metabolism of lipids and carbohydrates. To form the sulfhydryl-containing molecule pantetheine, pantothenic acid must combine with cysteamine. Cysteamine itself is formed through conjugation and decarboxylation reactions of cysteine. The disulfide form of pantetheine, known as pantethine, as opposed to pantothenic acid, bypasses cysteine conjugation and decarboxylation.

Pantethine is structurally related to coenzyme A and is found in the prosthetic group that is required for the biological function of acyl-carrier protein. It must be clearly distinguished from pantothenic acid (vitamin B5) and from calcium pantothenate, the most common supplemental form of vitamin B5. High doses of vitamin B5 do not result in the lipid changes seen with pantethine.

1.2 Natural Sources

Pantethine is the disulfide dimer of pantetheine, the 4′-phosphate derivative of which is an intermediate in the conversion of the B vitamin pantothenic acid to coenzyme A. Pantethine is found naturally in small quantities in most forms of life, and therefore, in food sources. It is not a classical botanical ingredient but rather an endogenously produced intermediate in human and animal metabolism. Foods rich in pantothenic acid — and by extension the pantethine precursor chain — include animal organs (liver and kidney), fish, shellfish, milk products, eggs, avocados, legumes, mushrooms, and sweet potatoes. The free pantethine present in dietary sources is minimal; supplemental pantethine used clinically is a synthesized compound.

1.3 Common Forms and Preparations

Pantothenic acid in dietary supplements is often in the form of calcium pantothenate or pantethine. Pantethine itself is available as a standalone dietary supplement as well as in combination cardiovascular and lipid-support formulas. Most vitamin B5 supplements are in the form of calcium pantothenate, a salt of pantothenic acid, with doses in the range of 5 to 10 mg/day. In contrast, pantethine is sold as a dietary supplement for lowering blood cholesterol and triglycerides at doses of 500 to 1200 mg/day.

Oral pantethine has been shown to be safe and effective, and an identical prescription product (Pantosin, a proprietary formulation of highly absorbable and biologically active pantethine) has been used in Japan for more than 30 years. In Japan and China, pantethine is available as a prescription drug for hyperlipidemia. Pantethine is available in the United States as a dietary supplement because of evidence for lowering elevated LDL-cholesterol and triglycerides and raising HDL-cholesterol.

Supplement dosage forms include oral tablets, capsules, and softgels. A commercially prominent and well-studied form is marketed under the tradename Pantesin®, which has been used in a number of published clinical trials.

2. Historical and Scientific Background

2.1 Discovery and Early Research

Pantethine was isolated and studied more extensively in the mid-to-late 20th century, as biochemical research into coenzyme A deepened. While pantothenic acid (vitamin B5) was discovered in the 1930s and rapidly adopted for its role in skin health, adrenal support, and wound healing, pantethine was later recognized as the metabolically superior form for lipid-lowering purposes. Pantethine was discovered by Gene Brown, a PhD student at the time.

By the 1970s and 1980s, pantethine gained attention in Japan and Europe, where early clinical trials demonstrated its efficacy in hyperlipidemia. It was used as a natural alternative to prescription lipid-lowering drugs, with a favorable safety profile and minimal side effects.

Unlike herbs or ancient remedies, pantethine does not have a traditional medical history in folk or botanical systems, as it is a nutrient-derived compound. Its clinical use history is therefore entirely rooted in 20th-century biochemistry and modern clinical pharmacology, rather than in ethnobotany or traditional medicine systems such as Ayurveda or Traditional Chinese Medicine.

2.2 Regulatory Context

In Japan and China, pantethine has been classified and used as a pharmaceutical agent for hyperlipidemia. In Japan and China, pantethine is available as a prescription drug for hyperlipidemia. In the United States and most of Europe, it is sold as a dietary supplement and is not subject to pharmaceutical approval requirements for that use. The form of pantothenic acid called pantethine is being studied to see if it helps lower total cholesterol, LDL cholesterol, and triglyceride levels, and is also being studied to see if it raises levels of HDL cholesterol. The results of these studies so far are promising, but more research is needed to understand the effects of pantethine dietary supplements taken alone or combined with a heart-healthy diet.

3. Key Constituents, Biochemistry, and Mechanisms of Action

3.1 Relationship to Coenzyme A Biosynthesis

Pantethine is the major precursor of coenzyme A, which plays a central role in the metabolism of lipids and carbohydrates. Coenzyme A is a cofactor in over 70 enzymatic pathways, including fatty acid oxidation, carbohydrate metabolism, pyruvate degradation, amino acid catabolism, haem synthesis, acetylcholine synthesis, phase II detoxification, and acetylation.

In supplement form, two pantotheines are joined as a disulfide for chemical stability, because pantetheine alone is unstable in air as the free thiol oxidizes. The disulfide is rapidly reduced to two pantetheine molecules in the body, where they can either be phosphorylated by pantothenate kinase (PANK) directly or, in some tissues, incorporated into the CoA biosynthesis pathway at a downstream step. Key point: pantethine bypasses the PANK rate-limiting step. This is why pantethine produces clinical effects (most notably on lipid metabolism) that pantothenate itself does not produce at comparable doses.

The disulfide form pantethine bypasses cysteine conjugation and decarboxylation. This might account for some of the clinical benefits seen with pantethine supplementation that have not been reproduced with the supplementation of pantothenic acid.

3.2 Mechanisms Proposed for Lipid-Modifying Effects

It has been postulated that pantethine acts by inhibiting the enzymes acetyl-CoA carboxylase and HMG-CoA reductase, thus modifying lipoprotein metabolism. However, the mechanism of action of pantethine in its role as a lipid-lowering agent is yet to be clarified.

Several proposed mechanisms are supported by cell-culture and biochemical data:

• Inhibition of fatty acid and cholesterol synthesis: Human cell culture studies with fibroblasts and hepatocytes have demonstrated the direct inhibitory influence of pantethine on lipid biosynthesis. In human skin fibroblast cultures, pantethine (100–200 mM) causes an 80% inhibition of cholesterol synthesis and a 50% inhibition of total fatty acid synthesis, as measured by the incorporation of radiolabeled acetate or mevalonolactone. In isolated hepatocytes, pantethine has been shown to inhibit both cholesterol and fatty acid synthesis.
• Enhancement of fatty acid oxidation: Pantethine produces a decrease in malonyl-CoA, leading to a decrease in fatty acid synthesis and an increase in fatty acid oxidation in mitochondria. In turn, plasma lipids are affected, especially by triacylglycerol-lowering effects.
• Enhancement of lipoprotein lipase: Pantethine is believed to enhance the activity of lipoprotein lipase, an enzyme that breaks down triglycerides in lipoproteins into free fatty acids and glycerol. This process facilitates the clearance of triglycerides from the blood and promotes their uptake and utilization by tissues.
• Gut microbiota modulation: Considering that gut microbiota (especially bacterial strains such as Lactobacillus and Bifidobacterium) aid in decreasing lipids in hyperlipidemic patients, and that pantethine promotes the survival and growth of various beneficial gut bacteria, it has been suggested that microbiota can contribute (at least in part) to a possible mechanism of pantethine action on circulating lipids.
• Antioxidant activity: The accepted mechanistic hypothesis for pantethine's lipid-modifying effect includes reduced lipid peroxidation. Pantethine's thiol chemistry (free or as the disulfide) provides modest antioxidant activity that may reduce oxidative modification of LDL particles, the proximate event in atherogenesis.
• Platelet function modulation: Supplementation with pantethine normalizes platelet fatty acid composition to a control value, leading to a significant reduction in platelet hyperaggregation. Some early studies reported reduced platelet aggregation with pantethine, which would be cardiovascular-protective independent of the lipid effect.

Pantethine can cross the membrane of cells and increase the availability of coenzyme A, which promotes the Szent-Györgyi–Krebs cycle and thereby stimulates the oxidation of acetate at the expense of fatty acid and cholesterol synthesis.

4. Scientific Evidence by Area of Use

4.1 Hyperlipidemia and Cardiovascular Lipid Profiles

This is the best-studied clinical application of pantethine, with multiple randomized clinical trials and a systematic review. The weight of evidence is moderate, with consistent directional findings but limitations in study size and duration.

4.1.1 The 2005 Systematic Review (McRae)

A 2005 review included 28 small clinical trials (average sample size of 22 participants) that examined the effect of pantethine supplements (median daily dose of 900 mg for an average of 12.7 weeks) on serum lipid levels in a total of 646 adults with hyperlipidemia. On average, the supplements were associated with triglyceride declines of 14.2% at 1 month and 32.9% at 4 months. The corresponding declines in total cholesterol were 8.7% and 15.1%, and for LDL cholesterol were 10.4% and 20.1%. The median daily dose in the included studies was 900 mg (range: 600 to 1,200).

The review was assessed by the DARE (Database of Abstracts of Reviews of Effects) at the University of York as a systematic review meeting inclusion criteria, but it should be noted that the underlying trials were predominantly small, short-duration, and mostly conducted in Italy and Japan.

4.1.2 Randomized Trial in High-CVD-Risk Subjects (Japan)

A prior published randomized, placebo-controlled, multicenter trial in Japan of 201 high-CVD-risk individuals demonstrated that 600 mg/day (given orally in 3 divided doses over 16 weeks) of pantethine lowered LDL-C by 15%, lowered TG by 14%, and raised HDL-C by 17% from baseline.

4.1.3 Rumberger et al. 2011 (Triple-Blinded, North American Population)

Safety and efficacy of pantethine on total cholesterol (TC) and LDL cholesterol metabolism was studied in North American subjects at conventional low to moderate CVD risk. A total of 120 subjects initiated a therapeutic lifestyle change (TLC) diet 4 weeks before randomization and maintained the diet throughout a 16-week study period; at baseline, subjects were randomized in a triple-blinded manner to either pantethine (600 mg/day, baseline to week 8, and 900 mg/day, weeks 9–16) or identically labeled, nonbiologically active placebo (n = 60 per group). While sustaining a TLC diet and in comparison with placebo, pantethine demonstrated significant (P < .005) and sustained reductions (from baseline to week 16) in TC (6 mg/dL, 3%), LDL-C (4 mg/dL, 4%), and apolipoprotein B (4 mg/dL, 5%).

The data suggest that pantethine supplementation for 16 weeks (600 mg/day for weeks 1–8 then 900 mg/day for weeks 9–16) is safe and significantly lowers TC and LDL-C over and above the effect of TLC diet alone. Although the absolute magnitude of these effects was small in these low- to moderate-risk North Americans (4–6 mg/dL), the results are noteworthy as prior studies have shown that, for each 1 mg/dL reduction in LDL-C, there is a concomitant 1% reduction in overall future CVD risk.

The limitations of this trial were documented by the authors: the length of the trial was a shortcoming, as after 16 weeks of pantethine administration the measured parameters had not plateaued, making prediction of the long-term outcome of pantethine on lipidemia difficult. Future clinical trials may demonstrate an even more robust decline. A small sample size and absence of sex stratification were also limitations of this study design.

4.1.4 Evans et al. 2014 (Triple-Blinded, Statin-Eligible Subjects)

A follow-on triple-blinded, placebo-controlled, diet-controlled investigation published in Vascular Health and Risk Management (2014) further examined pantethine in North American subjects who were eligible for statin therapy. Participants receiving pantethine had a 6% decrease in TC and 8% decrease in non-HDL-C, which was significantly different from participants on placebo who only had 2% and 1% decreases, respectively. The results confirmed that pantethine significantly improved cholesterol metabolism, by lowering TC and LDL-C, without causing serious adverse events in low- and moderate-CVD risk individuals eligible for statin therapy. Pantethine did not have an effect on TG levels, possibly because the enrolled participants had normal TG levels at baseline.

4.1.5 Coenzyme A vs. Pantethine Comparison (Chen et al. 2015)

A randomized, double-blind, multicenter study published in the Journal of Clinical Lipidology (2015) compared coenzyme A with pantethine for the treatment of hyperlipidemia; this study was cited by the NIH ODS health professional fact sheet as relevant evidence in this area. Several clinical trials have shown that the form of pantothenic acid known as pantethine reduces lipid levels when taken in large amounts, but pantothenic acid itself does not appear to have the same effects.

4.1.6 Overall Characterization of Lipid Evidence

The collective evidence indicates that pantethine produces consistent but modest reductions in total cholesterol, LDL-C, and triglycerides, and modest increases in HDL-C. In multiple clinical trials of patients with elevated cholesterol and triglycerides, total and LDL cholesterol were decreased by an average of 12%, triglycerides decreased by 19%, and HDL cholesterol was increased by 9% in clinical trials with daily intakes ranging from 600 to 1,200 mg/day. The evidence is stronger for triglyceride reduction and somewhat more modest for LDL-C effects, particularly in low-risk Western populations. Evidence strength is moderate overall: the findings are consistent across multiple trials and a systematic review, but the individual trials are small, most were short-term (under 4 months), and long-term cardiovascular outcome data (e.g., myocardial infarction, stroke) are absent. The NIH ODS notes that more research is needed.

4.2 Diabetes and Metabolic Disorders

Pantethine supplementation has some beneficial effects on parameters associated with platelet lipid composition and cell membrane fluidity. In diabetic patients, the lipid composition of platelets is significantly different from that of healthy subjects. Some early clinical studies, predominantly conducted in Italy and Japan in populations including diabetic subjects, have examined its lipid-modifying effects in this subgroup. As an alternative medicine, pantethine has been used to help lower cholesterol and triglycerides in diabetics. Clinical studies have shown that D-pantethine improves lipid profile in diabetic patients by lowering triglycerides and optimizing platelet lipid composition. The evidence base in this sub-population is preliminary and largely derived from older, small clinical trials. No high-quality, adequately powered RCTs specifically targeting glycemic outcomes with pantethine as the primary intervention have been identified in major databases.

4.3 Pantothenate Kinase-Associated Neurodegeneration (PKAN)

PKAN is a rare inherited neurodegenerative disorder caused by mutations in the PANK2 gene. Pantothenate kinase-associated neurodegeneration (PKAN, formerly Hallervorden–Spatz syndrome) is the most common neurodegeneration with brain iron accumulation (NBIA) disorder, with an estimated incidence of 1–3 per million and accounting for about half of NBIA cases. The discovery of the disease-causing mutations in PANK2 has linked the disorder to coenzyme A (CoA) metabolism.

The hypothesis that pantethine could bypass the PANK2 enzymatic blockade first emerged from animal research. Studies in the PANK Drosophila model "fumble" revealed improvement by the compound pantethine, which is hypothesized to feed an alternate CoA biosynthesis pathway. Supplementation of dPANK/fbl mutants with pantethine led to improvements in mobility and lifespan in affected flies, rescuing the neurodegenerative phenotype presumably by bypassing the metabolic blockade. Studies of pantethine as a potential therapeutic have been limited to Drosophila, although the compound has been utilized as a lipid-lowering agent in prior human studies.

More recently, a pilot human trial was conducted. After 24 weeks of treatment with pantethine at 60 mg/kg per day, there was no difference in either UPDRS I–III or FM score between the baseline and week 24. However, the rates of increase in UPDRS I–III and FM scores were slowed. Four patients (26.7%) were evaluated as "slightly improved" by doctors through blinded video assessment.

Pantethine could not significantly improve motor function in children with PKAN after 24 weeks of treatment, but it may delay the progression of motor dysfunction in this study. Pantethine was well-tolerated at 60 mg/kg per day.

The appropriate dose of pantethine for PKAN is unknown. The recommended dose for adults with hyperlipidemia is 600 mg per day (10 mg/kg per day), which is insufficient for patients with PKAN considering the concentration needed to work on the central nervous system.

Evidence in PKAN is preliminary: preclinical results in Drosophila and mouse models are encouraging, but a single small, non-randomized, open-label pilot trial in children constitutes the current human evidence. As is the case for most rare disorders, evidence-based guidance for the clinical management of PKAN is limited, often relying instead on anecdotal evidence, case reports and small series studies.

4.4 Cystinosis

Pantethine has been investigated as a source of cysteamine in nephropathic cystinosis, a lysosomal storage disease. D-pantethine is a conjugate of the vitamin pantothenic acid and the low-molecular-weight aminothiol cysteamine. Pantethine is an experimental hypolipemic agent and has been suggested as a source of cysteamine in the treatment of nephropathic cystinosis. Four cystinotic children were treated with 70–1,000 mg/kg per day oral D-pantethine, and its metabolism was studied.

Plasma cysteamine concentrations after pantethine were similar to those reported after equivalent doses of cysteamine. However, at best only 80% white blood cell cystine depletion occurred. The investigators concluded that pantethine is probably less effective than cysteamine in the treatment of nephropathic cystinosis and should only be considered in cases of cysteamine intolerance.

4.5 Antioxidant and Anti-Inflammatory Effects

Pantethine inhibits lipid peroxidation of the LDL-cholesterol fraction. The thiol (-SH) group in D-pantethine contributes to its antioxidant capacity, neutralizing reactive oxygen species (ROS) and protecting cell membranes from oxidative damage. These are largely mechanistic and in-vitro findings. Robust human clinical trials specifically designed to assess pantethine as an antioxidant agent in disease contexts have not been identified in the major peer-reviewed literature.

4.6 Alcohol Metabolism

Some preclinical research cited in review literature has explored pantethine's role in alcohol metabolism, specifically its potential to reduce acetaldehyde levels following alcohol ingestion. This research appears to be primarily early-phase, referenced in older studies with limited clinical follow-up.

4.7 Areas With Insufficient Human Evidence

Several areas — including adrenal function support, immune modulation, and hepatoprotection — have been discussed in review literature, but the evidence base for these applications in humans is either limited to animal models, cell studies, or older, small, poorly-controlled clinical investigations. Pantethine has claimed beneficial effects in vascular disease, including the ability to decrease hyperlipidemia, moderate platelet function, and prevent lipid peroxidation. Moreover, a neuro-endocrinological regulating role, as well as beneficial influence on cataract and cystinosis, have been reported. However, these latter claims are largely based on preclinical studies or very small older trials and are not supported by modern high-quality RCT evidence.

5. Body Systems and Health Areas

• Cardiovascular system: Best-evidenced area; clinically documented modest reductions in total cholesterol, LDL-C, non-HDL-C, triglycerides, apolipoprotein B, and modest elevation of HDL-C and apolipoprotein A1.
• Lipid and energy metabolism: Central role as a CoA precursor; involved in beta-oxidation of fatty acids, the Krebs cycle, and carbohydrate metabolism.
• Nervous system: Investigated (primarily preclinically) in PKAN and related neurodegeneration via the CoA pathway; limited human data from a single pilot trial.
• Hematological (platelet function): Early clinical evidence of effects on platelet aggregation and lipid composition, particularly in diabetic populations.
• Renal system: Investigated in nephropathic cystinosis as a cysteamine source; evidence suggests it is less effective than cysteamine for this indication.
• Hepatic system: Cell-culture and animal data suggest effects on hepatic lipid synthesis; limited human-specific evidence.

6. Dosage Forms and Dosages Reported in Studies

Pantethine is sold as a dietary supplement for lowering blood cholesterol and triglycerides at doses of 500 to 1,200 mg/day.

The following specific dosages are documented in published clinical studies:

• McRae 2005 systematic review (28 trials, n=646): The median daily dose in the included studies was 900 mg (range: 600 to 1,200 mg). Average treatment duration was 12.7 weeks.
• Rumberger et al. 2011 (North American, low-to-moderate CVD risk): 600 mg/day (baseline to week 8), escalating to 900 mg/day (weeks 9–16), in 120 subjects.
• Japanese multicenter RCT (high-CVD-risk subjects): 600 mg/day given orally in 3 divided doses over 16 weeks in 201 subjects.
• Evans et al. 2014 (statin-eligible subjects): Two randomized, blinded trials compared pantethine with placebo after 16 weeks; increasing the amount from 600 to 900 mg/day did not increase the magnitude of reduction in the lipid measures.
• Pilot PKAN trial (children): A dosage of 60 mg/kg per day was used in the study.
• Cystinosis (children): 70–1,000 mg/kg per day oral D-pantethine was studied.

For context of the dosing range, pantethine is regarded as a well-tolerated agent, with a median pantethine dosage of 900 mg/day showing 1.4 adverse reactions per 100 subjects, most of which were gastrointestinal complaints of mild severity.

7. Safety Considerations and Interactions

7.1 General Tolerability

This molecule is a well-tolerated therapeutic agent; the frequency of its side effects is very low and mild. A review on the medical aspects of pantethine states that the frequency of its side effects is very low and mild.

7.2 Adverse Effects Documented in Clinical Trials

Although D-pantethine is usually well tolerated, some people may experience gastrointestinal upset: nausea, vomiting, and diarrhea are the most common adverse reactions. Rare cases of atopic dermatitis and eczema have been documented.

In the 2014 North American RCT, specific adverse event data were documented: Diarrhea was moderate in intensity, experienced for 3 days during the 600 mg/day dosage period, and did not recur when the dosage was escalated. Flatulence reported by one participant was experienced during both dosage periods, was mild in intensity, and resolved prior to the end of the study. There was no drug-related adverse event during the PKAN pilot study.

7.3 Upper Intake Level

The Food and Nutrition Board (FNB) was unable to establish ULs for pantothenic acid because there are no reports of pantothenic acid toxicity in humans at high intakes. No separate tolerable upper intake level has been established specifically for pantethine.

7.4 Platelet Function and Bleeding Risk

There is some evidence that pantethine can slow blood clotting, so some healthcare providers worry that pantethine might increase the risk of severe bleeding in patients with bleeding disorders. High doses may increase the risk of bleeding, especially in people taking anticoagulants.

7.5 Drug Interactions

Pantothenic acid is not known to interact or interfere with any medicines. However, this caution is specifically for pantothenic acid at nutritional doses, not necessarily pantethine at the higher therapeutic doses used in lipid studies. D-pantethine may interact with anticoagulants and lipid-lowering medications. Medications that slow blood clotting (anticoagulant/antiplatelet drugs) carry a moderate interaction rating requiring caution.

7.6 Pregnancy and Lactation

There is not enough reliable information about the safety of taking pantethine if pregnant or breast-feeding. No clinical trials of pantethine have been conducted in pregnant or lactating women, and this population was excluded from the published lipid-lowering trials.

7.7 Preoperative Use

Pantethine might slow blood clotting, and there is a concern that it might increase the risk of extra bleeding during and after surgery.

References

• Horváth Z, Vécsei L. Current medical aspects of pantethine. Ideggyogy Sz. 2009;62(7-8):220-9. PubMed PMID: 19685700
• Linus Pauling Institute, Oregon State University. Pantothenic Acid. Micronutrient Information Center. Updated February 2026.
• PubChem (NIH). Pantethine. CID 452306. National Center for Biotechnology Information.
• NIH Office of Dietary Supplements. Pantothenic Acid: Fact Sheet for Health Professionals.
• NIH Office of Dietary Supplements. Pantothenic Acid: Fact Sheet for Consumers.
• Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects. Nutr Res. 2011;31(8):608-15.
• Evans M, Rumberger JA, Azumano I, et al. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy. Vasc Health Risk Manag. 2014;10:89-100. PMC3942300
• Database of Abstracts of Reviews of Effects (DARE). McRae MP. Treatment of hyperlipoproteinemia with pantethine: a review and analysis of efficacy and tolerability. Nutrition Research 2005;25(4):319-333. NCBI Bookshelf.
• Chang X, Zhang J, Jiang Y, et al. Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study. Orphanet J Rare Dis. 2020;15(1):248. PMC7491170
• Wittwer CT, Gahl WA, Butler JD, Zatz M, Thoene JG. Metabolism of pantethine in cystinosis. J Clin Invest. 1985;76(4):1665-72. PubMed PMID: 4056044
• Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Molecular Genetics and Metabolism. 2017. ScienceDirect.
• Czumaj A, et al. The Pathophysiological Role of CoA. Int J Mol Sci. 2020;21(23):9057. MDPI.
• Horváth Z, Vécsei L. Treatment with Pantethine. Topical Review Article. Alternative Therapies in Health and Medicine. SAGE Journals.
• Wikipedia. Pantethine. (Used for cross-reference of chemical synonyms and clinical trial summary data.)
• Kurian MA, Hayflick SJ. Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes. Int Rev Neurobiol. 2013;110:49-71. PubMed PMID: 22515741
• Brunetti D, et al. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain. 2014;137(Pt 1):57-68. PMC3891449